Nature of Business (Details Narrative) - USD ($)	12 Months Ended
	Dec. 31, 2021	Dec. 31, 2020	Dec. 13, 2019	Sep. 30, 2018	Jun. 01, 2018	Jul. 27, 2017	Dec. 31, 2011
Percentage of service charge					5.00%
Cash investments						$ 13,000,000
Investment in common stock per share			$ 5.00			$ 6.60
Common stock market price premium percentage						92.00%
Number of warrants issued to purchase shares of common stock						500,000
Warrrants exercise price per share						$ 6.60
Warrant expiration						Jan. 26, 2019
Fee contingent payments				$ 250,000		$ 343,000,000
Net income loss	$ 13,176,663	$ 6,700,606
Cash in operations	12,308,890	6,140,133
Accumulated deficit	484,075,711	470,727,380
Cash	6,769,603	$ 10,003,375
FDA [Member]
Payments for milestone	6,000,000
EMA [Member]
Payments for milestone	$ 4,000,000
Orphazyme [Member]
Fee contingent payments							$ 120,000,000